Ian Flinn - Center for Blood Cancers, Medical Oncology, Tennessee Oncology

基本信息

浏览量：597

职业迁徙

个人简介

Board Certifications
Hematology
Medical oncology

研究兴趣

论文共 660 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Table S2 from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies

Pinkal Desai,Sagar Lonial,Amanda Cashen, Manali Kamdar,Ian Flinn, Susan O’Brien, Jacqueline S. Garcia, Neha Korde,Javid Moslehi, Margaret Wey, Patricia Cheung, Shringi Sharma,

crossref（2024）

引用0浏览0引用

Genomic Landscape of Patients in a Phase II Study of Zanubrutinib in Ibrutinib- And/or Acalabrutinib-Intolerant Patients with B-cell Malignancies

Linlin Xu,Mazyar Shadman,Ian W. Flinn,Moshe Y. Levy,Ryan Porter,John M. Burke,Syed F. Zafar,Jennifer L. Cultrera,Jamal Misleh,Edwin C. Kingsley,Habte A. Yimer,Benjamin Freeman,

Haematologica (2024)

引用0浏览0WOS引用

Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma

Javier Munoz,Ian W. Flinn,Jonathon B. Cohen,Jessica Sachs, Benjamin Exter,Ann Ranger,Patricia Harris,Francis Payumo,Rajneesh Nath,Mehdi Hamadani,Jason R. Westin,Veronika Bachanova

TRANSPLANTATION AND CELLULAR THERAPYno. 2 (2024)

引用0浏览0WOS引用

Metabolic Tumor Volume Predicts Outcome in Patients with Advanced Stage Follicular Lymphoma from the RELEVANCE Trial

A. S. Cottereau,L. Rebaud,J. Trotman,P. Feugier,L. J. Nastoupil,E. Bachy,I. W. Flinn,C. Haioun,L. Ysebaert,N. L. Bartlett,H. Tilly,O. Casasnovas,

ANNALS OF ONCOLOGYno. 1 (2024): 130-137

引用0浏览0WOS引用

Magrolimab Plus Rituximab With/without Chemotherapy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Joseph Maakaron,Adam S. Asch,Leslie L. Popplewell,Graham P. Collins,Ian W. Flinn,Nilanjan Ghosh, Colin Keane,Matthew Ku,Amitkumar Mehta,Mark Roschewski,Carol O'Hear,Xuehan Ren,

Blood Advances（2024）

引用3浏览0WOS引用

Mosunetuzumab Safety Profile in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience from a Pivotal Phase I/II Trial

Matthew Matasar,Nancy L. Bartlett,Mazyar Shadman,Lihua E. Budde,Ian Flinn,Gareth P. Gregory,Won Seog Kim,Georg Hess,Dima El-Sharkawi,Catherine S. Diefenbach, Huang,Iris To,

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2024）

引用0浏览0引用

A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies

Pinkal Desai,Sagar Lonial,Amanda Cashen,Manali Kamdar,Ian Flinn,Susan O'Brien,Jacqueline S Garcia,Neha Korde,Javid Moslehi, Margaret Wey,Patricia Cheung,Shringi Sharma,

Clinical cancer research an official journal of the American Association for Cancer Researchno. 21 (2024): 4844-4855

引用0浏览0WOS引用

The Phase III DUO Trial of PI3K Inhibitor Duvelisib Versus Ofatumumab in Relapsed/refractory Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma: Final Analysis Including Overall Survival

Alexey V Danilov,Ian W Flinn,Matthew S Davids, Beth Gregory,Ohad Bentur,David Sidransky,Jennifer R Brown

Haematologicano. 10 (2024): 3379-3382

引用0浏览0WOS引用

Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy

Jennifer L. Crombie, Tara Graff,Lorenzo Falchi,Yasmin H. Karimi,Rajat Bannerji,Loretta Nastoupil,Catherine Thieblemont,Renata Ursu,Nancy Bartlett,Victoria Nachar,Jonathan Weiss, Jane Osterson,

BLOODno. 16 (2024): 1565-1575

引用0浏览0WOS引用

Magrolimab Plus Rituximab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Phase 1/2 Trial 3-Year Follow-up

Amitkumar Mehta,Leslie Popplewell,Graham P. Collins,Sonali M. Smith,Ian Flinn,Nancy L. Bartlett,Nilanjan Ghosh, Gal Hacohen Kleiman, Yanan Huo,Linda Su-Feher,Camille Renard,Ranjana Advani,

Blood Advances (2024)

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn